One-and-done behavior is especially common among obesity patients, as 19% of obesity GLP-1 users fill only a single prescription
Agents in this group include peroxisome proliferator-activated receptor agonists (e.g., pioglitazone, elafibranor, saroglitazar), bile acid-farnesoid X receptor axis regulators (obeticholic acid), de novo lipogenesis inhibitors (aramchol, NDI-010976), and fibroblast growth factor 21/19 analogs
TLDR: go easy
Trial data can help patients understand general medication trends, but a physician must interpret that information in the context of the individual patients health history, side-effect risk, current medications, and long-term goals
Phillipe OBrien was an employee of Eli Lilly and Company at the time of submission
Amino Acids: Essential building blocks for the production of neurotransmitters, reduce brain fog and increase energy levels